Saturday, July 5, 2025

Latest

Mind Medicine Closes The Year Out With Further Management Departures

Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO this past summer. Classified as “transitions,” the firm has lost both its Chief Technology Officer, as well as its Chief Scientific Officer.

The first executive to depart, Bradford Cross, is said to have “transitioned from his role,” although the company doesn’t state exactly what Cross is transitioning to – however Mind Medicine has been removed entirely from his LinkedIn page, while the company has removed any information on him from their website, indicating he has “transitioned” out of the company. Cross previously was lead on the firms digital therapeutics platform, which will now be lead by Chief Medical officer Dr Daniel Karlin.

Don Gehlert is the second departure from the company, whom will be leaving his role as Chief Scientific Officer. Instead, he will be servicing as a Senior Scientific Advisor, and “continue to be an integral part” of Mind Medicine. He meanwhile lists himself as a consultant for the firm on LinkedIn.

Mind Medicine last traded at $2.18 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Torex Gold Acquires Reyna Silver For CASH!

Dundee Acquires Adriatic Metals: The Balkan Growth Strategy

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

MindMed Expects Results For Anxiety, ADHD Trials By Late 2023

It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as...

Monday, January 9, 2023, 10:40:35 AM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM

MindMed Acquires HealthMode For $41.6 Million

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in...

Thursday, February 18, 2021, 08:21:32 AM